|
|
|
|
 |
Contents |
 |
|
|
|
|
|
|
|
|
|
|
|
* Residue conservation analysis
|
|
|
 |
|
|
 |
 |
 |
 |
Enzyme class 1:
|
 |
Chains A, B:
E.C.2.7.7.-
- ?????
|
|
 |
 |
 |
 |
 |
Enzyme class 2:
|
 |
Chains A, B:
E.C.2.7.7.49
- RNA-directed Dna polymerase.
|
|
 |
 |
 |
 |
 |
Reaction:
|
 |
DNA(n) + a 2'-deoxyribonucleoside 5'-triphosphate = DNA(n+1) + diphosphate
|
 |
 |
 |
 |
 |
DNA(n)
|
+
|
2'-deoxyribonucleoside 5'-triphosphate
|
=
|
DNA(n+1)
Bound ligand (Het Group name = )
matches with 55.56% similarity
|
+
|
diphosphate
|
|
 |
 |
 |
 |
 |
 |
 |
 |
Enzyme class 3:
|
 |
Chains A, B:
E.C.2.7.7.7
- DNA-directed Dna polymerase.
|
|
 |
 |
 |
 |
 |
Reaction:
|
 |
DNA(n) + a 2'-deoxyribonucleoside 5'-triphosphate = DNA(n+1) + diphosphate
|
 |
 |
 |
 |
 |
DNA(n)
|
+
|
2'-deoxyribonucleoside 5'-triphosphate
|
=
|
DNA(n+1)
|
+
|
diphosphate
|
|
 |
 |
 |
 |
 |
 |
 |
 |
Enzyme class 4:
|
 |
Chains A, B:
E.C.3.1.-.-
|
|
 |
 |
 |
 |
 |
Enzyme class 5:
|
 |
Chains A, B:
E.C.3.1.13.2
- exoribonuclease H.
|
|
 |
 |
 |
 |
 |
Reaction:
|
 |
Exonucleolytic cleavage to 5'-phosphomonoester oligonucleotides in both 5'- to 3'- and 3'- to 5'-directions.
|
 |
 |
 |
 |
 |
Enzyme class 6:
|
 |
Chains A, B:
E.C.3.1.26.13
- retroviral ribonuclease H.
|
|
 |
 |
 |
 |
 |
Enzyme class 7:
|
 |
Chains A, B:
E.C.3.4.23.16
- HIV-1 retropepsin.
|
|
 |
 |
 |
 |
 |
Reaction:
|
 |
Specific for a P1 residue that is hydrophobic, and P1' variable, but often Pro.
|
 |
 |
 |
 |
 |
 |
 |
|
Note, where more than one E.C. class is given (as above), each may
correspond to a different protein domain or, in the case of polyprotein
precursors, to a different mature protein.
|
|
 |
|
Molecule diagrams generated from .mol files obtained from the
KEGG ftp site
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
| |
|
|
| |
|
DOI no:
|
Biochemistry
37:14394-14403
(1998)
|
|
PubMed id:
|
|
|
|
|
| |
|
Crystal structures of HIV-1 reverse transcriptase in complex with carboxanilide derivatives.
|
|
J.Ren,
R.M.Esnouf,
A.L.Hopkins,
J.Warren,
J.Balzarini,
D.I.Stuart,
D.K.Stammers.
|
|
|
|
| |
ABSTRACT
|
|
|
| |
|
The carboxanilides are nonnucleoside inhibitors (NNIs) of HIV-1 reverse
transcriptase (RT), of potential clinical importance. The compounds differ in
potency and in their retention of potency in the face of drug resistance
mutations. Whereas UC-84, the prototype compound, only weakly inhibits many RTs
bearing single point resistance mutations, inhibition by UC-781 is little
affected. It has been proposed that UC-38 and UC-781 may form quaternary
complexes with RT at a site other than the known binding pocket of other NNIs.
X-ray crystal structures of four HIV-1 RT-carboxanilide complexes (UC-10, UC-38,
UC-84, and UC-781) reported here reveal that all four inhibitors bind in the
usual NNI site, forming binary 1:1 complexes with RT in the absence of
substrates with the amide/thioamide bond in cis conformations. For all four
complexes the anilide rings of the inhibitors overlap aromatic rings of many
other NNIs bound to RT. In contrast, the second rings of UC-10, UC-84, and
UC-781 do not bind in equivalent positions to those of other "two-ring" NNIs
such as alpha-APA or HEPT derivatives. The binding modes most closely resemble
that of the structurally dissimilar NNI, Cl-TIBO, with a common hydrogen bond
between each carboxanilide NH- group and the main-chain carbonyl oxygen of
Lys101. The binding modes differ slightly between the UC-10/UC-781 and
UC-38/UC-84 pairs of compounds, apparently related to the shorter
isopropylmethanoyl substituents of the anilide rings of UC-38/UC-84, which draws
these rings closer to residues Tyr181 and Tyr188. This in turn explains the
differences in the effect of mutated residues on the binding of these compounds.
|
|
|
|
|
|
|
 |
 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Literature references that cite this PDB file's key reference
|
|
 |
| |
PubMed id
|
 |
Reference
|
 |
|
|
|
 |
S.E.Nichols,
R.A.Domaoal,
V.V.Thakur,
J.Tirado-Rives,
K.S.Anderson,
and
W.L.Jorgensen
(2009).
Discovery of wild-type and Y181C mutant non-nucleoside HIV-1 reverse transcriptase inhibitors using virtual screening with multiple protein structures.
|
| |
J Chem Inf Model,
49,
1272-1279.
|
 |
|
|
|
|
 |
G.Barreiro,
C.R.Guimarães,
I.Tubert-Brohman,
T.M.Lyons,
J.Tirado-Rives,
and
W.L.Jorgensen
(2007).
Search for non-nucleoside inhibitors of HIV-1 reverse transcriptase using chemical similarity, molecular docking, and MM-GB/SA scoring.
|
| |
J Chem Inf Model,
47,
2416-2428.
|
 |
|
|
|
|
 |
G.Barreiro,
J.T.Kim,
C.R.Guimarães,
C.M.Bailey,
R.A.Domaoal,
L.Wang,
K.S.Anderson,
and
W.L.Jorgensen
(2007).
From docking false-positive to active anti-HIV agent.
|
| |
J Med Chem,
50,
5324-5329.
|
 |
|
|
|
|
 |
J.L.Medina-Franco,
K.Martínez-Mayorga,
C.Juárez-Gordiano,
and
R.Castillo
(2007).
Pyridin-2(1H)-ones: A Promising Class of HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors.
|
| |
ChemMedChem,
2,
1141-1147.
|
 |
|
|
|
|
 |
W.L.Jorgensen,
K.P.Jensen,
and
A.N.Alexandrova
(2007).
Polarization Effects for Hydrogen-Bonded Complexes of Substituted Phenols with Water and Chloride Ion.
|
| |
J Chem Theory Comput,
3,
1987-1992.
|
 |
|
|
|
|
 |
J.Ren,
C.E.Nichols,
A.Stamp,
P.P.Chamberlain,
R.Ferris,
K.L.Weaver,
S.A.Short,
and
D.K.Stammers
(2006).
Structural insights into mechanisms of non-nucleoside drug resistance for HIV-1 reverse transcriptases mutated at codons 101 or 138.
|
| |
FEBS J,
273,
3850-3860.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
T.Maruyama,
S.Kozai,
Y.Demizu,
M.Witvrouw,
C.Pannecouque,
J.Balzarini,
R.Snoecks,
G.Andrei,
and
E.De Clercq
(2006).
Synthesis and anti-HIV-1 and anti-HCMV activity of 1-substituted 3-(3,5-dimethylbenzyl)uracil derivatives.
|
| |
Chem Pharm Bull (Tokyo),
54,
325-333.
|
 |
|
|
|
|
 |
J.L.Medina-Franco,
A.Golbraikh,
S.Oloff,
R.Castillo,
and
A.Tropsha
(2005).
Quantitative structure-activity relationship analysis of pyridinone HIV-1 reverse transcriptase inhibitors using the k nearest neighbor method and QSAR-based database mining.
|
| |
J Comput Aided Mol Des,
19,
229-242.
|
 |
|
|
|
|
 |
E.N.Peletskaya,
A.A.Kogon,
S.Tuske,
E.Arnold,
and
S.H.Hughes
(2004).
Nonnucleoside inhibitor binding affects the interactions of the fingers subdomain of human immunodeficiency virus type 1 reverse transcriptase with DNA.
|
| |
J Virol,
78,
3387-3397.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
F.Daeyaert,
M.de Jonge,
J.Heeres,
L.Koymans,
P.Lewi,
M.H.Vinkers,
and
P.A.Janssen
(2004).
A pharmacophore docking algorithm and its application to the cross-docking of 18 HIV-NNRTI's in their binding pockets.
|
| |
Proteins,
54,
526-533.
|
 |
|
|
|
|
 |
J.D.Pata,
W.G.Stirtan,
S.W.Goldstein,
and
T.A.Steitz
(2004).
Structure of HIV-1 reverse transcriptase bound to an inhibitor active against mutant reverse transcriptases resistant to other nonnucleoside inhibitors.
|
| |
Proc Natl Acad Sci U S A,
101,
10548-10553.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
N.Sluis-Cremer,
N.A.Temiz,
and
I.Bahar
(2004).
Conformational changes in HIV-1 reverse transcriptase induced by nonnucleoside reverse transcriptase inhibitor binding.
|
| |
Curr HIV Res,
2,
323-332.
|
 |
|
|
|
|
 |
E.De Clercq
(2002).
New anti-HIV agents and targets.
|
| |
Med Res Rev,
22,
531-565.
|
 |
|
|
|
|
 |
P.P.Chamberlain,
J.Ren,
C.E.Nichols,
L.Douglas,
J.Lennerstrand,
B.A.Larder,
D.I.Stuart,
and
D.K.Stammers
(2002).
Crystal structures of Zidovudine- or Lamivudine-resistant human immunodeficiency virus type 1 reverse transcriptases containing mutations at codons 41, 184, and 215.
|
| |
J Virol,
76,
10015-10019.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
E.De Clercq
(2000).
Novel compounds in preclinical/early clinical development for the treatment of HIV infections.
|
| |
Rev Med Virol,
10,
255-277.
|
 |
|
|
|
|
 |
H.G.Hahn,
H.K.Rhee,
C.K.Lee,
and
K.J.Whang
(2000).
Designs and syntheses of oxathiin carboxanilide analogues and their antiviral activities.
|
| |
Arch Pharm Res,
23,
315-323.
|
 |
|
|
|
|
 |
J.Ren,
C.Nichols,
L.E.Bird,
T.Fujiwara,
H.Sugimoto,
D.I.Stuart,
and
D.K.Stammers
(2000).
Binding of the second generation non-nucleoside inhibitor S-1153 to HIV-1 reverse transcriptase involves extensive main chain hydrogen bonding.
|
| |
J Biol Chem,
275,
14316-14320.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
J.Ren,
J.Diprose,
J.Warren,
R.M.Esnouf,
L.E.Bird,
S.Ikemizu,
M.Slater,
J.Milton,
J.Balzarini,
D.I.Stuart,
and
D.K.Stammers
(2000).
Phenylethylthiazolylthiourea (PETT) non-nucleoside inhibitors of HIV-1 and HIV-2 reverse transcriptases. Structural and biochemical analyses.
|
| |
J Biol Chem,
275,
5633-5639.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
J.Ren,
J.Milton,
K.L.Weaver,
S.A.Short,
D.I.Stuart,
and
D.K.Stammers
(2000).
Structural basis for the resilience of efavirenz (DMP-266) to drug resistance mutations in HIV-1 reverse transcriptase.
|
| |
Structure,
8,
1089-1094.
|
 |
|
PDB codes:
|
 |
|
|
 |
 |
|
The most recent references are shown first.
Citation data come partly from CiteXplore and partly
from an automated harvesting procedure. Note that this is likely to be
only a partial list as not all journals are covered by
either method. However, we are continually building up the citation data
so more and more references will be included with time.
Where a reference describes a PDB structure, the PDB
codes are
shown on the right.
|
');
}
}
 |